Abstract
Background: Many atherosclerotic cardiovascular disease (ASCVD) patients on statin therapy, despite well-controlled LDL-C levels, still suffer recurrent ASCVD events. Little information is known about the specific risk factors associated with increased residual risk. Methods: We studied 3,196
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
